| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T558 |
0-45 |
Sentence |
denotes |
Figure 18 Scheme of CaPNPs used for vaccine. |
| T559 |
46-51 |
Sentence |
denotes |
Left: |
| T560 |
52-132 |
Sentence |
denotes |
CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. |
| T561 |
133-143 |
Sentence |
denotes |
Top right: |
| T562 |
144-206 |
Sentence |
denotes |
CaPNPs were able to reduce cell-to-cell virus spread in vitro. |
| T563 |
207-220 |
Sentence |
denotes |
Bottom right: |
| T564 |
221-279 |
Sentence |
denotes |
CaP nanovaccines were able to immunize mice against HSV-1. |
| T565 |
280-322 |
Sentence |
denotes |
Reproduced with permission from ref (153). |
| T566 |
323-351 |
Sentence |
denotes |
Copyright 2019 Elsevier B.V. |
